The International Myeloma Foundation announces the launch of a new program created in partnership with Medscape Oncology that offers healthcare professionals an opportunity to earn continuing medical education (CME) credit. “Everything You Need to Know About Continuous Treatment in Multiple Myeloma” is a series of online educational courses for hematology/oncology specialists, nurses, and pharmacists.
Moderated by Dr. Brian G.M. Durie (Chairman of the Board, the International Myeloma Foundation, and Multiple Myeloma Specialist, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai, Los Angeles), the panelists include the following myeloma specialists:
- Rafat Abonour, MD, (Professor of Medicine, Indiana University School of Medicine, Indianapolis)
Beth Faiman, PhD, CNP, Nurse Practitioner (Multiple Myeloma Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland) - Thomas Martin, MD (Clinical Professor of Medicine, Associate Director, Myeloma Program, University of California, San Francisco Medical Center, San Francisco)
- Joseph Mikhael, MD (Professor of Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute, City of Hope Cancer Center, and Chief Medical Officer, International Myeloma Foundation)
- Robert A. Vescio, MD, (Medical Director, Multiple Myeloma and Amyloidosis Program, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles)
Topics covered in this educational activity include:
- Continuous Treatment of Transplant-Ineligible Patients
- After Transplant: The Role of Maintenance with or Without Prior Consolidation
- Selecting Myeloma Maintenance Therapy for High-Risk Patients
- Multiple Myeloma Maintenance Therapy: How Long Do I Treat?
- Management of Adverse Events Associated With Maintenance Therapy
- Key Takeaways and Future Directions
The goal of this activity is to increase the knowledge and competence of hematologists/oncologists and other clinicians who care for patients with multiple myeloma in the areas of treatment selection for transplant-ineligible patients, maintenance therapy, and management of therapy-related adverse events.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Upon completion, participants will have increased knowledge regarding treatment options, best practices among members of the care team, and monitoring for, identifying, and treating common therapy-related adverse events in patients with MM receiving consolidation or maintenance therapy.
Source: Biospace